Nemolizumab, which targets the interleukin-31 pathway, rapidly improves itch and sleep in people with atopic dermatitis and ...

Vixarelimab showed rapid, sustained itch reduction and good safety in prurigo nodularis. Learn more about the study and ...

Prurigo nodularis is an extremely itchy skin condition. It causes a rash that often includes hard lumps called nodules. You might also hear it called nodular prurigo. Doctors don’t know exactly what ...

A new study published in The Journal of Dermatology showed that prurigo nodularis is associated with a considerably higher ...

Prurigo nodularis (PN) is a rare skin condition. It causes a rash and lumps to form on your skin, which may be severely itchy. Treatment involves relieving the itching. Share on Pinterest Prurigo ...

Despite the approval of dupilumab (Dupixent) in September 2022, there is an ongoing dearth of clinically effective treatments for prurigo nodularis, prompting the present investigation of the ...

The Food and Drug Administration has approved dupilumab for treating adults with prurigo nodularis, the first treatment approved for this indication, according to a press release from the ...

In a randomized clinical trial, vixarelimab demonstrates dose-dependent, long-term safety and efficacy in patients with ...

Dupixent, an interleukin-4 receptor alpha antagonist, is the first treatment indicated for prurigo nodularis. Credit: Getty Images. The Food and Drug Administration (FDA) has approved Dupixent ® ...

Vakharia is assistant professor of dermatology at Northwestern University Feinberg School of Medicine in Chicago. The information here represents his knowledge and experience as a medical professional ...

Please provide your email address to receive an email when new articles are posted on . These studies are the first published using Dupixent in this indication. The primary endpoint was met by up to ...

The FDA has granted nemolizumab Priority Review for the treatment of prurigo nodularis. The Food and Drug Administration (FDA) has accepted for review the Biologics License Applications (BLA) for ...